The estimated Net Worth of Jed Latkin is at least $740 Thousand dollars as of 20 February 2020. Mr. Latkin owns over 5,000 units of Navidea Biopharmaceuticals Inc stock worth over $18 and over the last 8 years he sold NAVB stock worth over $0. In addition, he makes $739,943 as Chief Executive Officer, Chief Financial Officer, and Chief Operating Officer at Navidea Biopharmaceuticals Inc.
Sign up
Mr. Latkin NAVB stock SEC Form 4 insiders trading
Jed has made over 6 trades of the Navidea Biopharmaceuticals Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of NAVB stock worth $5,400 on 20 February 2020.
The largest trade he's ever made was buying 25,359 units of Navidea Biopharmaceuticals Inc stock on 19 May 2017 worth over $11,412. On average, Jed trades about 3,124 units every 67 days since 2016. As of 20 February 2020 he still owns at least 17,950 units of Navidea Biopharmaceuticals Inc stock.
You can see the complete history of Mr. Latkin stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Jed Latkin biography
Jed A. Latkin serves as Chief Executive Officer, Chief Financial Officer, Chief Operating Officer of the Company. he has served as Chief Executive Officer of Navidea since October 2018, and as Chief Operating Officer and Chief Financial Officer of Navidea since May 2017. Mr. Latkin also served as Interim Chief Operating Officer of Navidea from April 2016 to April 2017. Mr. Latkin has more than twenty years of experience in the financial industry supporting many investments in major markets including biotechnology and pharmaceuticals. He most recently was employed by Nagel Avenue Capital, LLC since 2010 and in that capacity he provided contracted services as a Portfolio Manager, Asset Based Lending for Platinum Partners Value Arbitrage Fund L.P. Mr. Latkin has been responsible for a large diversified portfolio of asset-based investments in varying industries, including product manufacturing, agriculture, energy, and healthcare. In connection with this role, he served as Chief Executive Officer of End of Life Petroleum Holdings, LLC and Black Elk Energy, LLC, Chief Financial Officer of Viper Powersports, Inc. and West Ventures, LLC, and Portfolio Manager of Precious Capital, LLC. Mr. Latkin served on the board of directors for Viper Powersports, Inc. from 2012 to 2013 and served on the boards of directors of the Renewable Fuels Association and Buffalo Lake Advanced Biofuels. Mr. Latkin earned a B.A from Rutgers University and a M.B.A. from Columbia Business School.
What is the salary of Jed Latkin?
As the Chief Executive Officer, Chief Financial Officer, and Chief Operating Officer of Navidea Biopharmaceuticals Inc, the total compensation of Jed Latkin at Navidea Biopharmaceuticals Inc is $739,943. There are no executives at Navidea Biopharmaceuticals Inc getting paid more.
How old is Jed Latkin?
Jed Latkin is 46, he's been the Chief Executive Officer, Chief Financial Officer, and Chief Operating Officer of Navidea Biopharmaceuticals Inc since 2019. There are 6 older and no younger executives at Navidea Biopharmaceuticals Inc. The oldest executive at Navidea Biopharmaceuticals Inc is William J. Regan, 69, who is the Chief Strategy Officer & Chief Compliance Officer.
What's Jed Latkin's mailing address?
Jed's mailing address filed with the SEC is 711 STEWART AVE., SUITE 200, , GARDEN CITY,, NY, 11530.
Insiders trading at Navidea Biopharmaceuticals Inc
Over the last 13 years, insiders at Navidea Biopharmaceuticals Inc have traded over $3,167,813 worth of Navidea Biopharmaceuticals Inc stock and bought 7,718,496 units worth $6,241,151 . The most active insiders traders include John K Jr. Scott, Perry A Karsen, and Life Sciences, Llc Platinum.... On average, Navidea Biopharmaceuticals Inc executives and independent directors trade stock every 63 days with the average trade being worth of $159. The most recent stock trade was executed by John K Jr. Scott on 10 April 2022, trading 3,260 units of NAVB stock currently worth $3.
What does Navidea Biopharmaceuticals Inc do?
navidea biopharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. it operates through two segments, diagnostic substances and therapeutic development programs. the company develops manocept platform to target the cd206 mannose receptor expressed on activated macrophages. its cd206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (pet), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. further, the company offers nav4694, a fluorine-18 labeled pet imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of alzheimer's disease and mild cognitive impairment. in addition, it is de
What does Navidea Biopharmaceuticals Inc's logo look like?
Complete history of Mr. Latkin stock trades at ProPhase Labs Inc and Navidea Biopharmaceuticals Inc
Navidea Biopharmaceuticals Inc executives and stock owners
Navidea Biopharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Jed Latkin,
Chief Executive Officer, Chief Financial Officer, Chief Operating Officer -
Dr. Michael Stanley Rosol Ph.D.,
Sr. VP & Chief Medical Officer -
Michael Rosol,
Chief Medical Officer -
Y. Michael Rice,
Independent Chairman of the Board -
S. Kathryn Rouan,
Independent Director -
Adam Cutler,
Independent Director -
Claudine Bruck,
Independent Director -
Dr. Michel Mikhail Ph.D.,
Chief Regulatory Officer -
Jeffrey Smith,
VP of Operations -
Joel Harrison Kaufman,
Chief Bus. Officer -
William J. Regan,
Chief Strategy Officer & Chief Compliance Officer -
Erika Gibson,
Director of Fin. & Admin. -
Alexander L Cappello,
Director -
Anthony S. Fiorino,
Director -
Mark I Greene,
Director -
Brent L Larson,
EVP, CFO, Treas and Secy -
Gordon A Troup,
Director -
Eric K Rowinsky,
Director -
Thomas J Klima,
SVP & Chief Commercial Ofc -
William J. Regan,
SVP-Global Regulatory Strategy -
Michael M Goldberg,
Director -
Frederick O Cope,
Senior VP and CSO -
John K Jr. Scott,
-
Life Sciences, Llc Platinum...,
-
Rodger A Brown,
Vice President -
Perry A Karsen,
Director -
Thomas H. Tulip,
President -
Mark Platinum Management (N...,
-
Brendan A Ford,
Director -
Mark Jerome Pykett,
Pres. & CEO -
Cornelia Reininger,
SVP & Chief Medical Officer -
Jess Jones,
Director -
Anton Gueth,
Director -
Dana J Moss,
-
Joel H. Kaufman,
Chief Business Officer -
Malcolm G Witter,
Director -
Amit Bhalla,
Director -
Michel Mikhail,
Chief Regulatory Officer -
Agnieszka Winkler,
Director -
Thomas F Farb,
Director -
Joshua M. Wilson,
Director -
Jill Stefanelli,
-
Craig Dais,
CHIEF FINANCIAL OFFICER